Evidence map›Paper›PMID 42737517›Full record

ReviewInternational journal of molecular sciences2026

Integrating Radiogenomics and CSF-Based Liquid Biopsy Sequencing for Precision Neuro-Oncology.

Klaudia Kubiak, Edyta Szurowska

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Klaudia KubiakSecond Department of Radiology, Medical University of Gdańsk, 80-210 Gdańsk, Poland.ORCID 0000-0001-9696-504X
Edyta SzurowskaSecond Department of Radiology, Medical University of Gdańsk, 80-210 Gdańsk, Poland.ORCID 0000-0002-7042-4381

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma and diffuse gliomas pose major therapeutic challenges due to marked intratumoral heterogeneity, limited tissue accessibility, and the blood-brain barrier. Tissue-based next-generation sequencing (NGS) remains essential for WHO CNS5 molecular classification, yet it is invasive and poorly suited to serial monitoring. Two complementary non- or minimally invasive approaches have advanced rapidly: radiogenomics, which correlates multiparametric MRI features with genomic alterations, and cerebrospinal fluid (CSF) liquid biopsy sequencing, which detects circulating tumor DNA with high tissue concordance. This review examines the independent progress and synergistic integration of radiogenomics and CSF-NGS. Imaging signatures can non-invasively predict key drivers (

Indexed as

Brain NeoplasmsGenomicsGliomaPrecision MedicineBiomarkers, TumorCirculating Tumor DNAHigh-Throughput Nucleotide SequencingHumansLiquid BiopsyMagnetic Resonance ImagingBiomarkers, TumorCirculating Tumor DNAcerebrospinal fluidcirculating tumor DNAglioblastomagliomaliquid biopsynext-generation sequencingprecision neuro-oncologyradiogenomics

Identifiers

PMID42737517
PMCPMC13566500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.